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1. ABSTRACT 
In the last decades, the main focus of molecular imaging of Parkinson's disease has been on 
non-dopaminergic systems involved in the disease alongside the pathognomonic 
dopaminergic changes. Molecular imaging can detect, in vivo, both presynaptic and 
postsynaptic serotonergic changes in the brain and has played a key role in elucidating the 
pathophysiology of the serotonergic system in Parkinson's disease. Alterations in the 
serotonergic system may happen very early in the course of the disease and have shown a 
leading role in the development of tremor and dyskinesias, and in several non-motor 
symptoms, including sleep, cognitive and neuropsychiatric disturbances. These studies 
increasingly recognize that the regional topography of serotonergic brain areas associates with 
specific dysfunctions. In parallel with this trend, more recent molecular serotonergic imaging 
approaches are investigating serotonergic modulatory treatment and their contributions to 
the improvement of cognitive functions. In this review, we discussed post-mortem, 
preclinical and imaging evidence of serotonergic system changes in Parkinson's disease, and 
described how disease-specific serotonergic changes are relevant for motor and non-motor 
symptoms and complications. Future directions of serotonergic imaging have been also 
described alongside with the novel findings on the role of serotonergic system in 
asymptomatic LRRK2 carriers. 
 
Key words  
Serotonin; Parkinson’s disease; Sleep; Depression; Cognition; DASB; Tremor; Dyskinesias. 
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2. INTRODUCTION 
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases and is 
characterized by cardinal motor symptoms, including tremor, bradykinesia, and rigidity (Pagano, 
Ferrara, Brooks, & Pavese, 2016; Pagano, Polychronis, et al., 2018), mainly due to a deficit of 
dopaminergic terminals. PD patients also experience a plethora of non-motor symptoms, 
including sleep problems (Pagano, Molloy, et al., 2016; H. Wilson, Giordano, Turkheimer, 
Chaudhuri, & Politis, 2018; Yousaf, Pagano, Niccolini, & Politis, 2018a, 2018b), depression 
(Politis, Wu, Loane, Turkheimer, et al., 2010), chronic fatigue (Pavese, Metta, Bose, Chaudhuri, 
& Brooks, 2010), weight loss (Politis, Loane, Wu, Brooks, & Piccini, 2011), constipation 
(Pagano, Tan, Haider, Bautista, & Tagliati, 2015; Pagano, Yousaf, et al., 2018), urinary 
dysfunction (Pagano, Niccolini, Yousaf, et al., 2017), cognitive (Niccolini et al., 2017; Schulz, 
Pagano, Fernandez Bonfante, Wilson, & Politis, 2018) and neuropsychiatric disturbances (Maillet 
et al., 2016; Politis, Wu, Loane, Turkheimer, et al., 2010; Schrag & Politis, 2016). The 
development of non-motor symptoms is mainly due to the dysfunction of non-dopaminergic 
terminals (Qamhawi et al., 2015).  
 
The pathognomonic diagnostic feature of PD is a loss of dopaminergic neurons in the substantia 
nigra pars compacta (Jellinger, 1991) and the main pathological process is the accumulation of 
Lewy body pathology. However, Lewy body pathology is not confined to the dopaminergic 
system but involves also the serotonergic, cholinergic and noradrenergic systems (Buddhala et 
al., 2015; Kish, 2003). According to the Braak’s staging theory of PD, pathological processes 
begin early in the serotonergic raphe nuclei, prior to the onset of motor symptoms, and precede 
damage of the substantia nigra (Braak et al., 2003). Furthermore, post-mortem studies (Buddhala 
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et al., 2015; Kish et al., 2008), have shown that the serotonergic system is damaged in PD, with 
loss of synaptic terminals in serotonin-containing neurons including the raphe nuclei (Paulus & 
Jellinger, 1991). 
 
Serotonin, also called 5-hydroxytryptamine (5-HT), is one of the most widely distributedand the 
serotonergic system virtually innervates all brain areas (Fox, Chuang, & Brotchie, 2009). This 
diversity of function is manifested by the large number and wide distribution of 5-HT receptors 
(Fox et al., 2009). To date, there are 14 distinct subtypes of the 5-HT receptor, with many more 
isoforms; this large number has been suggested to reflect the fact that the 5-HT system is one of 
the oldest neurotransmitter systems in evolutionary terms and has thus had the longest to diversify 
(Fox et al., 2009). 
 
Positron emission tomography (PET) molecular imaging is a powerful analytical method to detect 
in vivo changes in the brain (Pagano, Niccolini, & Politis, 2016; Pagano, Yousaf, & Politis, 2017; 
Politis & Niccolini, 2015; Politis, Pagano, & Niccolini, 2017; Roy, Niccolini, Pagano, & Politis, 
2016). PET used together with specific serotonin radioligands has played a key role in elucidating 
the pathophysiology of serotonergic system in PD (Pagano, Niccolini, Fusar-Poli, & Politis, 2017; 
Pagano, Niccolini, & Politis, 2017).  
 
In this review, we will discuss post-mortem, preclinical and imaging evidence suggesting 
serotonergic system changes in PD. We will also review molecular serotonergic imaging studies 
in PD and discuss how disease-specific serotonergic changes are relevant for motor and non-
motor symptoms and motor complications. Finally, we will discuss novel findings on the role of 
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the serotonergic system in familial PD, focusing on asymptomatic carriers of the leucine-rich 
kinase 2 (LRRK2) gene mutation. 
 
3. MOLECULAR IMAGING TECHNIQUES TO STUDY SEROTONERGIC 
SYSTEM CHANGES IN PARKINSON’S DISEASE 
Molecular imaging ligands have been developed for PET to allow in vivo visualization of 
presynaptic 5-HT transporter (SERT) and post-synaptic serotonergic receptors targets. Figure 1 
provides an overview of the major serotonergic imaging ligands currently available for studies in 
humans. 
 
** Insert Figure 1 ** 
 
The first PET tracer developed to image the SERT levels was the [11C]McN5652 (Suehiro, 
Scheffel, Ravert, Dannals, & Wagner, 1993; Szabo et al., 1995; Szabo et al., 2002; Szabo et al., 
1999). [11C]McN5652 has a relatively high specificity and selectivity for the SERT (Szabo et al., 
1999), with a tracer distribution that correlates well with the known distribution of the SERT in 
humans, and yields a reliable assessment of SERT binding with a documented loss of 5-HT 
innervation (McCann, Szabo, Scheffel, Dannals, & Ricaurte, 1998; Scheffel et al., 1998).  Kerenyi 
and colleagues employed [11C]McN5652 to study the serotoninergic system in PD (Kerenyi et al., 
2003). The [11C]McN5652 binding was quantified with the (apparent) total distribution volume 
that was derived from a 1-compartment, 3-parameter model (Szabo et al., 1999). The distribution 
volume of specific binding was calculated as (DVtotal - DVcer)/DVcer, where DVcer is the 
radioligand distribution volume in the cerebellum (Frey et al., 1996). They evaluated 13 patients 
  9 
with idiopathic PD compared to 13 normal controls by using [11C]McN5652 PET to assess the 
SERT availability, [11C]WIN35428 PET to assess the dopamine transporter (DAT) and [15O]H2O 
PET to assess the blood flow (Kerenyi et al., 2003). Binding of [11C]McN5652 was reduced in 
the caudate and the putamen of PD patients along with the expected reductions in striatal 
[11C]WIN35428 binding. The distribution volume of the cerebellum, used to assess non-specific 
binding of [11C]McN5652, was not statistically different between controls and PD patients, with 
no significant covariance effect of age. Unlike [11C]WIN35428, [11C]McN5652 binding was not 
disproportionately reduced in striatal nuclei contralateral to the more affected side of the body 
among PD patients with asymmetric tremor or rigidity. A trend for reduced [11C]McN5652 
binding in the thalamus was also observed. There were no reductions in regional cerebral blood 
flow or the sizes of the regions of interest, brain atrophy, or partial volume effects. Reductions in 
[11C]McN5652 binding correlated with ratings of UPDRS-III disease staging. However, despite 
these promising findings, in regions with moderate-to-low SERT density, the quantification of 
[11C]McN5652 is not so reliable due to high non-specific binding and [11C]McN5652 scans 
required long imaging sessions in order to acquire accurate SERT measures (Frankle et al., 2004).  
 
To overcome the limitations of the first generation PET ligand for SERT, a tracer called [11C]-3-
Amino-4-(2-dimethylaminomethylphenylsulfaryl)-benzonitrile ([11C]DASB) was developed (A. 
A. Wilson et al., 2000). [11C]DASB is a second generation PET ligand with higher selectivity for 
the SERT (compared to [11C]McN5652, [11C]DASB is three orders of magnitude more selective 
for SERT than for DAT or noradrenaline transporter) (Hummerich et al., 2004; A. A. Wilson et 
al., 2000; A. A. Wilson, Jin, Garcia, DaSilva, & Houle, 2001), and higher specific-to-nonspecific 
binding ratios (Frankle et al., 2004). Recently, the different approaches used for the quantification 
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of cerebral SERT binding using the tracer [11C]DASB have been reviewed (Norgaard et al., 2018). 
One-hundred and five original research articles published by 21 different PET centers have used 
[11C]DASB PET imaging, showing reliable results when a given preprocessing pipeline was 
applied (Norgaard et al., 2018). 
 
Over the past years [11C]DASB PET studies have demonstrated SERT changes in patients with 
PD (Pagano, Niccolini, Fusar-Poli, et al., 2017), which were associated with the development of 
tremor, dyskinesias, and non-motor symptoms such as depression, weight changes and fatigue. 
[11C]DASB PET has been also employed to investigate associations between SERT changes and 
olfactory dysfunction, rapid eye movement sleep behavior disorder, and sleep-disordered 
breathing in PD without significant correlations (Pagano, Niccolini, Fusar-Poli, et al., 2017). 
[11C]DASB binding in early PD patients has been reported either reduced or within normal levels 
(Pagano, Niccolini, Fusar-Poli, et al., 2017). Only studies in PD depression demonstrated relative 
increased [11C]DASB binding in patients with PD depression compared to non-depressed PD 
patients (Pagano, Niccolini, Fusar-Poli, et al., 2017).  
 
We recently systematically reviewed all [11C]DASB PET studies in PD (Pagano, Niccolini, Fusar-
Poli, et al., 2017). The serotonergic system was investigated in 234 PD patients across 20 PET 
studies. PD patients showed a reduction of serotonergic terminals in the raphe nuclei, thalamus, 
hypothalamus, ventral striatum, caudate and putamen, which correlated with the duration of the 
disease. 
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PET imaging has also been employed to assess 5-HT receptors in vivo. [18F]MPPF for 5-HT1A, 
[18F]setoperone for 5-HT2A, and [11C]AZ10419369 for 5-HT1B receptors are some of the examples 
of selective PET tracers available for studying the serotonin system in the human brain (Ballanger 
et al., 2012; Ballanger et al., 2010; Costes et al., 2007; Varnas et al., 2011). 5-HT receptors are a 
group of G protein-coupled receptor and ligand-gated ion channels expressed in the brain and in 
the peripheral nervous systems (Beliveau et al., 2017). 5-HT receptors are activated by the 
neurotransmitter 5-HT and involved in both excitatory and inhibitory neurotransmission. The 
main role of the 5-HT receptors is to modulate the release of other neurotransmitters, including 
glutamate, GABA, dopamine, noradrenaline, and acetylcholine and, thus, influencing several 
processes, including aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, 
sleep, and thermoregulation. They are targets of a variety of pharmaceutical and recreational 
drugs, including antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, 
antimigraine agents, hallucinogens, and entactogens (Johnston, Lu, & Rudd, 2014). There are 
several PET ligands that can bind to 5-HT receptors, as indicated in Table 1. 
 
** Insert Table 1 ** 
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4. SEROTONERGIC SYSTEM CHANGES IN PARKINSON’S DISEASE 
The vast majority of 5-HT producing-cell are located in a group of nuclei in the brainstem defined 
as the raphe. The raphe nuclei are subdivided on the basis of their distribution and main 
projections into two groups: the rostral raphe with major projections to the forebrain innervating 
the striatum and the limbic system (hypothalamus, amygdala, cingulum, the medial cerebral 
cortex and part of the hippocampus), and the caudal raphe with major projections to the caudal 
brainstem and to the spinal cord (Hornung, 2003). Several functions have been attributed to the 
serotonergic system including cognition, emotion and motor behavior; thus, altered serotonergic 
neurotransmission may contribute to the motor and non-motor features commonly associated with 
PD (Politis & Niccolini, 2015; Politis et al., 2017). Evidence from animal and human studies has 
suggested that striatal serotonergic terminals may contribute in the development of LIDs by 
promoting a non-physiological release of dopamine (Pagano, Niccolini, & Politis, 2017; Politis 
& Niccolini, 2015; Politis et al., 2017; Politis et al., 2014). 
 
4.1.Post-mortem studies 
In early post-mortem studies of patients with PD, depletion of 5-HT in the caudate as well as 
hypothalamus and frontal cortex was reported, although not to the same degree as dopamine loss 
(Hartmann, 2004). A recent pathological study has confirmed some of these findings, showing 
preferential loss of 5-HT in the caudate compared with the putamen, but with relatively less loss 
of 5-HT (66%) than dopamine (98%) (Kish et al., 2008). The common link between 
neurodegeneration in the serotonergic system may be the presence of Lewy bodies, which stresses 
their importance in PD pathogenesis and explains the high prevalence of depression (Politis, Wu, 
Loane, Turkheimer, et al., 2010), dementia (Kotagal, Spino, Bohnen, Koeppe, & Albin, 2018), 
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and sleep disorders in PD (H. Wilson et al., 2018). According to Braak’s staging, the pathological 
process in PD occurs in a gradual ascending fashion, starting from the olfactory nucleus and the 
medulla in presymptomatic stages and spreading to the pons and midbrain later (Braak et al., 
2003). In Braak stage 2, Lewy body and Lewy neurite deposition occurs within the median raphe 
nuclei containing the serotonergic neurons of the caudal brainstem (Braak et al., 2003). These 
data suggest that caudal brainstem serotonergic neurons are affected before dopaminergic 
midbrain neurons while in the midbrain the two systems should be affected simultaneously. 
 
4.2.Preclinical studies 
Experimental studies have demonstrated a key role of the serotonergic system in the development 
of LIDs and of non-motor symptoms, including sleep-related disturbances. In preclinical models 
of PD induced by 6-hydroxy (6-OH) dopamine, the number of striatal serotonin terminals has 
been associated with both striatal dopamine peaks and abnormal involuntary movements (AIMs) 
scores (Gil, Park, Lee, Minn, & Koh, 2011). In addition, it has been demonstrated that dopamine 
release from serotonergic terminals is ectopic in terms of both subcellular release sites and 
anatomical distribution. The lesion induced by 6-OH dopamine is associated with a large increase 
in dopamine levels after levodopa administration in several brain areas, including the 
hippocampus and prefrontal cortex, richly innervated by serotonergic pathways. These increases 
are totally abolished by a complete lesion of serotonin neurons (Navailles, Bioulac, Gross, & De 
Deurwaerdere, 2010). The AIMs are alleviated by removing striatal serotonin afferents (Carta, 
Carlsson, Kirik, & Bjorklund, 2007) and by blocking serotonergic transmission with 5-HT1A and 
5-HT1B agonists (Bezard et al., 2013; Eskow, Gupta, Alam, Park, & Bishop, 2007; Munoz et al., 
2009; Munoz et al., 2008). However, low doses of 5-HT1A and 5-HT1B agonists are able to 
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suppress only the mild levodopa-induced AIMs, but they do not reduce the moderate-severe 
apomorphine-induced AIMs (Munoz et al., 2009). These findings confirm that the activation of 
pre-synaptic receptors account for the effect of combined low doses of 5-HT1A and 5-HT1B 
agonists on mild dyskinesias, whereas other mechanisms may explain the more severe 
apomorphine-induced AIMs. These results have been confirmed in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) monkey models of PD (Bezard et al., 2013; Rylander et al., 
2010). MPTP monkeys show increased serotonergic terminals in the striatum (Rylander et al., 
2010) and a positive anti-dyskinetic effect of 5-HT1A and 5-HT1B agonist anpirtoline (Bezard et 
al., 2013). This evidence further confirms an abnormal sprouting of serotonin terminals in PD, 
suggesting a key role of serotonergic system in the development of LIDs. 
 
In terms of non-motor symptoms, the lesion of raphe nuclei is associated with lower brain levels 
of serotonin and the development of reduction of sleep in experimental models (Jouvet, 1972). In 
experimental studies with sleep deprivation, it has been found a reduction of the SERT (by using 
[11C]DASB PET) in the anterior olfactory nucleus and substantia nigra in rats that have been 
deprived of sleep when compared to control rats without sleep deprivation (Hipolide et al., 2005). 
 
 
4.3.Imaging studies 
Over the past years [11C]DASB PET studies have demonstrated SERT changes in patients with 
PD. Staging of  SERT dysfunction in PD patients has shown reductions of [11C]DASB binding in 
the caudate, thalamus, hypothalamus, and anterior cingulate cortex in early PD patients followed 
by additional [11C]DASB binding reductions in the putamen, insula, posterior cingulate cortex, 
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and prefrontal cortex in patients with established PD (Politis, Wu, Loane, Kiferle, et al., 2010). 
Advanced PD patients showed further [11C]DASB binding reductions in the ventral striatum, 
raphe nuclei and amygdala. A recent meta-analysis of [11C]DASB PET imaging studies have 
shown that PD patients have a reduction of serotonergic terminals in the raphe nuclei, thalamus, 
hypothalamus, ventral striatum, caudate and putamen, which correlates with the duration of the 
disease (Pagano, Niccolini, Fusar-Poli, et al., 2017). This suggests that the progressive loss of 
synaptic terminals in PD affects the serotonergic system and is not only confined to the 
dopaminergic terminals. However, PD patients who experienced LIDs showed preserved 
serotonergic terminals compared to PD patients with stable response to levodopa. These findings 
indicate that although serotonergic system progressively degenerates in PD disease, those who 
develop LIDs have an aberrant spreading of serotonergic terminals or a faster degeneration of 
dopaminergic than serotonergic terminals. Several imaging studies have been performed aiming 
to understand the how disease-specific serotonergic changes are relevant for motor and non-motor 
symptoms and complications. These studies are described below in each specific paragraph.  
 
5. SEROTONERGIC SYSTEM CHANGES AND MOTOR SYMPTOMS IN 
PARKINSON’S DISEASE 
The development of tremor in PD has been speculated to be underlined by non-dopaminergic 
mechanisms due to the fluctuating response of this symptom to dopaminergic supplementation 
and the lack of correlations with dopaminergic molecular imaging markers. PET studies with 
[11C]DASB have shown reduced binding in the caudate, putamen, raphe nuclei and thalamus of 
tremor-dominant PD patients when compared with those who had akinetic-rigid phenotype, and 
a correlation between [11C]DASB binding in the caudate, putamen and raphe nuclei and tremor 
  16 
scores (Loane et al., 2013). Serotonergic pathology has also been associated with the development 
of the motor complications LIDs and graft-induced dyskinesias (GIDs) (Pagano, Niccolini, & 
Politis, 2017). Parkinson’s patients who experienced LIDs and GIDs have an aberrant spreading 
of serotonergic terminals, which lead to an increased serotonergic/dopaminergic terminals ratio 
within the putamen. Serotonergic terminals convert exogenous levodopa into dopamine in a non-
physiological manner and release an abnormal amount of dopamine without an auto-regulatory 
feedback. This results in higher swings in synaptic levels of dopamine, which leads to the 
development of LIDs and GIDs. The modulation of serotonergic terminals with 5-HT1A and 5-
HT1B receptors agonists partially reduced these motor complications. However, other systems 
also play a role in the development of these motor complications (Pagano, Niccolini, & Politis, 
2017). 
 
5.1.Tremor 
Tremor is considered one of the diagnostic feature of PD, but also the most difficult to diagnose. 
Although is usually asymmetric and mainly present on the most affected side of the body during 
rest, it can also be seen on the “wrong side” of the body (contralateral to the side of more severe 
bradykinesia) and “in action” often with a short pause in the transition from rest to posture. This 
has been called re-emergent tremor but also other type of tremors are present in PD. Some patients 
show a distinct postural tremor clearly different from re-emergent tremor based either on the 
frequency (which is often faster than resting tremor) or the lack of tremor at rest. Another postural 
tremor can be essential tremor, and there is an increased incidence of PD in patients with essential 
tremor. It also can be dystonic tremor, and this might even look similar to classic tremor and has 
been suggested that the scans without evidence of dopamine deficiency patients have dystonic 
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tremor (Taylor et al., 2016). Additionally, a patient can have an exaggerated physiological tremor. 
However, the so-called “re-emergent tremor” is currently considered a variant of resting tremor 
and should be differentiated from the postural tremor typically observed in patients with essential 
tremor and from the physiological tremor typically observed in the elderly (Belvisi et al., 2017). 
Considering its complexity, it is easy to understand why tremor is one of the most challenging 
symptoms to manage in clinic, with a poor and unpredictable response to treatment compared to 
bradykinesia and rigidity (Koller & Hubble, 1990). Evidence from PET and SPECT molecular 
imaging studies have shown that dopamine transporter is less affected in tremor-dominant 
compared with akinetic-rigid patients and that tremor does not correlate with dopamine 
transporter levels, assessed with [123I]FP-CIT SPECT (Asenbaum et al., 1998),  dopamine 
terminal capacity, assessed with [18F]FDOPA PET (Brooks et al., 1992), nor dopamine D2 
receptor availability, assessed with [11C]raclopride PET (Pavese et al., 2006), which  suggests that 
this symptom could be associated with non-dopaminergic mechanisms. 
 
PET imaging studies have been performed in PD patients with tremor using [11C]WAY100635 
(Doder et al., 2003), a selective marker of 5-HT1A receptors, and [11C]DASB (Loane et al., 2013), 
a selective marker of SERT levels. In the first study, they found in 26 PD patients compared to 8 
healthy controls that midbrain raphe 5-HT1A binding was reduced by 27% in PD patients and 
there was a correlation between reductions in midbrain raphe 5-HT1A binding and the severity of 
resting tremor (Doder et al., 2003). In the second study, we found in 12 patients with tremor 
dominant PD, compared to 12 with akinetic-rigid PD, and 12 healthy controls, that SERT was 
reduced by 30% in the caudate, putamen, raphe nuclei, thalamus, and Brodmann areas 4 and 10 
in patients with tremor-dominant PD and there was a correlation between reductions in caudate, 
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putamen, and raphe nuclei [11C]DASB binding and the severity of postural and action tremor. It 
is important to underline that the scale used to quantify the tremor (MDS-UPDRS) cannot 
differentiate between postural and “re-emergent tremor”, thus, it is possible to speculate that the 
findings of the [11C]DASB study could actually show a correlation between SERT and this 
specific form of resting tremor, in line with the findings of [11C]WAY100635 study. However, in 
the [11C]DASB study, no correlations were found between SERT levels and tremor at-rest scores, 
which further confirms the complexity of tremor in PD suggesting that more than one mechanisms 
is involved in the development of this symptom. 
 
5.2. Dyskinesias 
Levodopa induces sharp increases in striatal dopamine levels, which are particularly elevated in 
PD patients who experience LIDs (Pagano, Niccolini, Fusar-Poli, et al., 2017). However, a 
moderate-to-severe loss of dopaminergic terminals in the dorsal putamen is a necessary condition 
for the development of LIDs, This is associated with the inability of remaining dopaminergic 
terminals to remove the released dopamine and to store it into the pre-synaptic vesicles. In these 
circumstances, the same amount of levodopa administered induces higher release of dopamine in 
the extracellular space (augumented dopamine percent change from basal levels) (Lindgren, 
Andersson, Lagerkvist, Nissbrandt, & Cenci, 2010). This results in higher swings in synaptic 
levels of dopamine and pulsatile stimulation of postsynaptic receptors located on striatal 
projection neurons (Pagano, Niccolini, Fusar-Poli, et al., 2017). At the same time, in absence of 
enough intact dopaminergic terminals, exogenous levodopa is metabolized in other terminals 
expressing the enzyme aromatic L-amino acid decarboxylase, such as serotonergic, which do not 
possess the molecular machinery to properly control the release of dopamine (Carta, Carlsson, 
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Munoz, Kirik, & Bjorklund, 2010). Since serotonergic neurons lack of an auto-regulatory 
feedback of dopamine release, serotonergic terminals will release dopamine in a non-
physiological manner. This results in higher swings in synaptic levels of dopamine and pulsatile 
stimulation of post-synaptic receptors located on striatal projection neurons (Carta & Bezard, 
2011).  
 
Four [11C]DASB PET studies have been performed in PD patients, investigating the LIDs. In the 
first PET study (Politis et al., 2014), we compared PD patients with LIDs to those with stable 
response to levodopa in term of serotonergic terminals density and striatal dopamine release. We 
measured serotonergic terminals by using [11C]DASB PET imaging and dopamine release by 
using [11C]raclopride PET, a D2 receptor antagonist radioligand which competes with 
endogenous dopamine for D2 receptor binding. Changes in D2 receptor availability, as reduction 
of baseline [11C]raclopride levels after levodopa administration, allows an indirect measure of 
synaptic dopamine release. PD patients with LIDs showed increased dopamine release after the 
administration of levodopa compared to those with stable response to levodopa, with a relative 
preservation of serotonergic terminals in the putamen (Politis et al., 2014). Oral administration 
prior to levodopa of the 5-HT1A receptor agonist buspirone, a pre-synaptic modulator of 
serotonergic system, reduced levodopa-evoked striatal synaptic dopamine release and attenuated 
LIDs (Politis et al., 2014). To note, among patients with LIDs, the antidyskinetic effect of 
buspirone was greater in those with higher levels of serotonergic terminals, who also exhibited a 
greater decrease in dopamine release after buspirone pretreatment (Politis et al., 2014). We also 
divided the patients with LIDs into two groups based on the severity of LIDs severity (milder 
versus severe forms). We found that buspirone-associated modulation of dopamine levels was 
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greater in patients with milder LIDs compared to those with more severe LIDs (Politis et al., 
2014). This suggests that in PD patients who experiences more severe LIDs, higher doses or 
stronger 5-HT1A agonists are needed to achieve similar suppression of LIDs. Another possibility, 
however, is that other downstream mechanisms, such as glutamatergic overactivity, could play a 
more dominant role in generating severe dyskinesias, and therefore the combined use of an 5-
HT1A agonist and an NMDA antagonist may be needed. This is in line with the preclinical 
experimental evidence previously described (Munoz et al., 2009), in which 5-HT1A and 5-HT1B 
agonists were able to suppress the mild levodopa-induced AIMs, but not to reduce the moderate-
severe apomorphine-induced AIMs (Munoz et al., 2009). Overall the findings from this study 
provide the first human evidence and indicate that striatal serotonergic terminals contribute to 
LIDs pathophysiology via aberrant processing of exogenous levodopa and release of dopamine 
as false neuro-transmitter in the denervated striatum of PD patients with LIDs. The results also 
support the development of selective 5-HT1A receptor agonists for use as antidyskinetic agents. 
We then investigated the role of serotonergic innervation of the globus pallidus in the 
development of dyskinesias (Smith et al., 2015). We measured the density of serotonergic 
terminals and the striatal dopamine release in the globus pallidus of PD patients with LIDs 
compared to those with stable response to levodopa by using [11C]DASB PET and [11C]raclopride 
challenge, respectively. PD patients with LIDs showed preserved serotonergic terminals in the 
globus pallidus, with a level similar to healthy controls. Higher density of serotonin terminals in 
the globus pallidus correlated with a greater amount of dopamine released and greater severity of 
LIDs. This indicates that either the serotonin terminal function in the globus pallidus in patients 
with LIDs is spared or, that an adaptive terminal sprouting of remaining serotonergic projections 
occurs not only in the putamen but also in the globus pallidus. Taking together this finding 
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(preserved serotonergic terminals in the globus pallidus) and the previous one (preserved 
serotonergic terminals in the putamen), we suggest that the imbalance caused by a normalization 
of serotonin terminals in the dopamine-denervated striatum creates increased dopamine release 
after levodopa administration, resulting in an increased negative input to the globus pallidus 
neurons controlling thalamic output. Greater LIDs might be the results of increased dopamine 
release at presynaptic dopaminergic receptors located at the synapses of striato-pallidal 
GABAergic neurons in the globus pallidus. These neurons control the projection neurons to the 
thalamus and thereby the thalamic output. By over-inhibition of these neurons, the dysregulated 
basal ganglia output then results in LIDs. This is in line with the preclinical evidence of a profound 
suppression of globus pallidus output activity in monkeys experiencing LIDs (Papa, Desimone, 
Fiorani, & Oldfield, 1999). In the third study (Roussakis, Politis, Towey, & Piccini, 2016), we 
investigated the interaction between serotonergic and dopaminergic terminals in the development 
of LIDs. We measured the density of serotonergic and dopaminergic terminals in the striatum of 
PD patients with LIDs and of patients with stable response to levodopa by using [11C]DASB PET 
and [123I]FP-CIT SPECT, respectively. We found that higher putaminal serotonergic-to-
dopaminergic terminals ratio correlate with longer disease duration in PD patients, indicating that, 
as PD progresses, the ratio between serotonergic and dopaminergic terminals becomes higher, as 
reflected by the higher [11C]DASB PET to [123I]FP-CIT SPECT binding ratio. This might be due 
to a faster progression of dopaminergic terminals compared to serotonergic ones, or to an aberrant 
sprouting of serotonergic innervation in the patients who will experience LIDs, as previously 
demonstrated in animal studies (Carta et al., 2007; Carta et al., 2010). In parallel, a fourth PET 
study from another team, has also shown that, compared to non-dyskinetic patients, PD patients 
with LIDs had a higher striatal serotoninergic to dopaminergic terminals availability, as reflected 
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by the higher [11C]DASB to [18F]FP-CIT PET binding ratio, with no difference in striatal 
dopaminergic terminals (Lee et al., 2015). 
 
Overall these findings suggest that when the dopaminergic innervation in the striatum is critically 
low, the serotonergic system plays an important role in development of LIDs (Figure 2). These 
findings support the role of serotonergic terminals in the aberrant release of striatal dopamine and 
in promoting the development of LIDs in patients with PD.  
 
** Insert Figure 2 ** 
 
Another troublesome involuntary movement associated with serotonergic system is the GIDs. 
Transplantation with foetal ventral mesencephalic tissue aimed to restore the dopaminergic 
terminals in advanced cases of Parkinson’s disease. This treatment showed tremendous efficacy 
in some patients with remarkable improvement of motor symptoms but some of them developed 
GIDs, a complication similar to LIDs but presents in ‘off’ their dopaminergic treatment (Freed et 
al., 1992; Freed et al., 1990; Hagell et al., 2002; Levivier et al., 1997; Lindvall et al., 1990; 
Lindvall et al., 1992; Ma et al., 2002; Olanow et al., 2009; Peschanski et al., 1994; Widner et al., 
1992). Graft tissue contained a varied proportion of non-dopaminergic cells including 
serotonergic neurons. Thus, striatal graft tissue containing high levels of serotonin neurons leads 
to mishandling of striatal dopamine levels resulting in the occurrence of GIDs (Politis, 2010; 
Politis, Oertel, et al., 2011; Politis, Wu, Loane, Quinn, et al., 2010). We have demonstrated that 
the same serotonergic mechanisms, such as excessive striatal serotonergic innervation and high 
serotonin to dopamine striatal terminal ratio, are pivotal in the development of GIDs in 
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Parkinson’s patients who underwent striatal transplantation with foetal ventral mesencephalic 
tissue (Politis, 2010; Politis, Oertel, et al., 2011; Politis, Wu, Loane, Quinn, et al., 2010). We 
evaluated the density of serotonergic terminals, by using [11C]DASB PET imaging, and the 
presynaptic dopaminergic amino acid aromatic decarboxylase terminals’ activity, by using 
[18F]DOPA PET imaging, in three Parkinson’s patients who received striatal transplantation with 
foetal ventral mesencephalic tissue and exhibited GIDs. All three patients showed an excessive 
graft-derived serotonergic innervation (Politis, Wu, Loane, Quinn, et al., 2010) and high serotonin 
to dopamine terminal ratio (Politis, Oertel, et al., 2011). Furthermore, administration of small, 
repeated doses of 5-HT1A receptor agonist buspirone, was able to attenuate graft-induced 
dyskinesias possibly by attenuating the abnormal serotonin terminal-derived dopamine release. 
These findings support the involvement of the serotonergic system in the development of GIDs 
and indicate that a ‘close-to-normal’ striatal serotonin/dopamine ratio in the transplanted foetal 
ventral mesencephalic tissue should be necessary to avoid the development of GIDs.  
 
6. SEROTONERGIC SYSTEM CHANGES AND NON-MOTOR SYMPTOMS IN 
PARKINSON’S DISEASE 
6.1.Sleep disturbances 
Approximately two-third of PD patients develop sleep-related problems in the course of the 
disease (Goetz, Wuu, Curgian, & Leurgans, 2005). They include rapid eye movement (REM) 
behavior disorder (RBD), insomnia, sleep apnoea, restless leg syndrome, sleep attacks and 
excessive daytime sleepiness (EDS) (Yousaf et al., 2018a, 2018b). Serotonergic system has a key 
role in the regulation of sleep patterns and the damage of raphe’s serotonergic neurons and 
projections is relevant in the development of sleep-related problems in PD. Preclinical data have 
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shown that a damage of raphe nuclei is associated with the onset of sleep problems (Jouvet, 1972) 
and in experimental studies with sleep deprivation, by using [11C]DASB PET, it has been found 
a reduction in the anterior olfactory nucleus and substantia nigra in rats that have been deprived 
of sleep when compared to control rats without sleep deprivation (Hipolide et al., 2005). In 
humans, the use of selective serotonin reuptake inhibitors (SSRIs) in the treatment of depression 
is commonly associated with the development of sleep alterations (Rush et al., 1998), which 
further confirms the theory that serotonergic system is relevant for the development of sleep 
disturbances. 
 
Sleep-related problems in PD might both have a presynaptic and a postsynaptic component. By 
using [11C]DASB PET imaging, we recently demonstrated that sleep dysfunction in PD is 
associated with reduced SERT in the midbrain raphe, basal ganglia and hypothalamus (H. Wilson 
et al., 2018). Compared to healthy controls, PD patients with sleep dysfunction had a 32–49% 
reduction of SERT, while PD without sleep dysfunction had only 14–25%. The reduction was 
higher in serotonergic raphe nuclei and their related projections (hypothalamus, thalamus and 
striatum) and correlated with greater severity of sleep symptoms (assessed with Parkinson 
Disease Sleep Scale). By using [18F]altanserin PET imaging, it has been shown that a single night 
of sleep deprivation induces an increase in cortical 5-HT2A receptors (medial inferior frontal 
gyrus, insula, anterior cingulate, parietal, sensomotoric, and ventrolateral prefrontal cortices) in 
healthy volunteers. This confirms a role for the serotonergic dysfunction in the onset of insomnia. 
However, the involvement of serotonergic system might not be homogenous across all sleep-
related disorders. In PD patients with sleep apnea, the levels of SERT in the raphe, measured by 
using [11C]DASB PET, were not associated with the severity (Lelieveld et al., 2012). In PD 
  25 
patients with RBD, it has been shown no changes in SERT levels but a reduction in brain 
cholinergic activity (Kotagal, Albin, et al., 2012), with lower thalamic, limbic cortex and 
neocortical [11C]PMP PET binding in PD patients with RBD compared to PD patients without 
RBD. Cholinergic changes, especially in brainstem and subcortical circuits, may contribute to 
this parasomnia.  
 
6.2. Depression 
Approximately 50% of PD patients develop mood disturbances in the course of the disease (Zhuo 
et al., 2017). Monoaminergic neurotransmitter changes, in particular 5-HT,  play a key role in the 
development of depression (Remy, Doder, Lees, Turjanski, & Brooks, 2005) and represent the 
major pharmacological target to treat this disorder (Weintraub et al., 2005). Imaging studies in 
patients with major depression (Cannon et al., 2007) and with bipolar (Cannon et al., 2006; 
Cannon et al., 2007) disorder have shown an increased [11C]DASB binding in the insula, thalamus 
and striatum compared to healthy controls, suggesting that increased SERT density could account 
for symptoms of depression by leading to increased clearance of serotonin from the synapse. 
However, the serotonergic component of depression in PD might involve both presynaptic and 
postsynaptic terminal dysfunction. Compared to PD patients without depression, PD patients with 
depression showed a reduction in CSF 5-hydroxyindoleacetic acid levels, the principal metabolite 
of 5-HT (Mayeux et al., 1986). In PET studies using [11C]DASB, PD patients with depression 
have reported relative increases of SERT binding in limbic structures compared to non-depressed 
PD patients (Boileau et al., 2008; Politis, Wu, Loane, Turkheimer, et al., 2010). The increase was 
greater in the dorsolateral (37%) and prefrontal (68%) cortices and correlated with depressive 
symptoms (assessed by the Hamilton Depression Rating Scale) (Boileau et al., 2008). We also 
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demonstrated an increase in subcortical SERT levels, in the amygdala, hypothalamus, raphe 
nuclei, and posterior cingulate cortex in PD patients with depressive symptoms compared to 
matched-PD patients without depression. This increase in [11C]DASB binding was indeed 
correlated with depressive symptoms (as assessed by Beck Depression Inventory-II and Hamilton 
Depression Rating Scale) (Politis, Wu, Loane, Turkheimer, et al., 2010). In the limbic regions of 
depressed PD patients, it has also been found a decrease in 5-HT1A receptors by using [18F]MPPF 
PET imaging (Ballanger et al., 2012), which is in agreement with post-mortem evidence (Sharp 
et al., 2008) and support the hypothesis that there is also a postsynaptic in the development of 
depression in PD (Ballanger et al., 2012). 
 
Overall, these findings suggest that in PD, as in major and bipolar depression, an excessive 5-HT 
clearance by SERT induces a reduced extracellular concentration of 5-HT leading to the 
development of depressive symptoms. However, the prevalence of depression in PD is higher 
compared to non-PD population and this could be explained by the concurrent decrease in 5-HT1A 
receptors and loss of serotonergic terminals in limbic regions. Thus, depression in PD could be 
the result of a combined effect of serotonergic terminal loss, inappropriate upregulation of SERT 
and reduced postsynaptic efficacy of the already depleted 5-HT. However, it should be noted that 
the pathophysiology of depression is complex and involves changes in multiple circuits and 
neurotransmitters beyond the serotonergic system likely in a dynamic and interactive way. 
 
6.3.Fatigue 
Approximately 75% of PD patients reported that fatigue affects their quality of life and often goes 
undetected, due to an uncertain pathological basis and lack of specific treatment (Chaudhuri & 
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Behan, 2000). Fatigue can be secondary to depression and anxiety due to the association between 
PD disability and this symptom fatigue. This suggests that the serotonergic system could be also 
implicated in development of fatigue in PD (Hagell & Brundin, 2009). 
 
A study using combined [18F]DOPA and [11C]DASB PET investigated the role of 5-HT in PD 
patients with fatigue (Pavese et al., 2010). Seven PD patients with fatigue and eight PD patients 
without fatigue, matched for age, disease duration and severity, daily intake of levodopa 
equivalent units, and with no history of depression or sleep disturbance, were compared using a 
region of interest analytical approach. PD patients with fatigue had about 70% reductions in 
[11C]DASB binding in the putamen, caudate nucleus, ventral striatum, thalamus, cingulate and 
amygdala, compared to the PD patients without fatigue, but striatal [18F]DOPA uptake was similar 
(Pavese et al., 2010). This observation suggests that the presynaptic component of serotonergic 
system plays a significant role in fatigue in PD. However, further research using other ligands, 
such as postsynaptic 5-HT receptors tracer, is needed to further investigate this area. 
 
6.4.Weight loss 
Approximately half of the PD patients develop weight loss over the course of the disease (Beyer, 
Palarino, Michalek, Busenbark, & Koller, 1995). Several mechanisms have been suggested to 
explain this loss of weight, including changes in energy expenditure, perturbation of homeostatic 
control, and eating behaviors (Kistner, Lhommee, & Krack, 2014). The main risks factors 
identified are the progression of the disease, the age of onset, and the level of disabilities (Uc et 
al., 2006), but the precise mechanisms involved in the development of weight loss are not fully 
understood. Serotonergic projections to the hypothalamus may influence homeostatic metabolic 
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regulation and weight loss can be secondary to the damage of serotonergic system. Serotonergic 
neurons also express considerable amounts of orexin receptor and dense orexin fiber projections 
(Eriksson, Sergeeva, Haas, & Selbach, 2010) and 5-HT plays a role in eating behavior. On the 
other hand, the diet can also influence 5-HT. The main precursor of 5-HT biosynthesis in the 
brain is the essential amino acid tryptophan. Carbohydrates intake induces an increase of insulin 
that enhances cerebral uptake of tryptophan, thus, increasing 5-HT biosynthesis (Wurtman & 
Wurtman, 1996). This explains the craving for carbohydrates of people with depression, due to 
their 5-HT-mediated positive effect on mood (Wurtman & Wurtman, 1996). Alterations of the 
serotonergic system in PD may explain the pronounced preference for carbohydrates and the 
increased intake of chocolate in this population (Wolz et al., 2009). Moreover, it has been 
described an abnormal regulation of growth hormone secretion by the serotonin receptors in 
response to receptor agonists in early drug-naïve PD patients compared to healthy controls (Volpi 
et al., 1997). These findings suggest that the 5-HT may be involved in weight changes observed 
in PD. We evaluated with [11C]DASB PET the relationship between body mass index (BMI) 
changes and serotonergic dysfunction in PD (Politis, Loane, et al., 2011). PD patients with 
abnormal BMI changes over a 12-month period showed significantly increase of [11C]DASB 
binding in rostral raphe nuclei, hypothalamus, caudate nucleus and ventral striatum compared to 
cases with no significant BMI alterations. BMI gainers showed an increase in [11C]DASB binding 
in anterior cingulate cortex, which is a central region modulating hunger (Politis, Loane, et al., 
2011). Therefore, BMI changes seem to be related to relatively raised SERT availability in rostral 
raphe nuclei and its connections to limbic and cognitive areas. 
 
6.5.Cognitive disturbances 
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About 80% of PD patients develop cognitive disturbances in the course of the disease {Aarsland, 
2010 #5680}. We demonstrated a key role of cholinergic nucleus basalis of Meynert in the 
initiation of the process (Schulz et al., 2018), but several components are needed in the 
development of dementia. Misfolded proteins, including α-syncleinopathy, β-amyloidopathy, 
tauopathy, are considered primum movens in the development of neuronal and synaptic 
dysfunctions, that leads to reduced glucose metabolic and cerebral blood flow, and impairment 
of brain network connectivity (Kalia, 2017). The presence of β-amyloid plaques has been 
associated with dementia in post-mortem PD studies (Kotzbauer et al., 2012). In vivo β-amyloid 
plaques in PD have been associated with more severe cognitive impairment (Shah et al., 2016). 
Experimental evidence suggests that Aβ production is modulated by synaptic activity and by 
activation of specific neurotransmitter receptors, including serotonin receptors (Shen et al., 2011). 
Preclinical studies suggest that augmentation of serotoninergic neurotransmission by SSRIs can 
reduce extracellular cerebral Aβ deposition and plaque burden (Cirrito et al., 2011). 5-HT and 
SSRIs can stimulate G-protein-coupled receptors and induce the cleavage of Amyloid Precursor 
Protein by α-secretase, leading to a reduction in Aβ1-42 generation and reduced plaque formation 
(Cirrito et al., 2011). SSRIs may also promote the efflux of Aβ1-42 from the brain to the 
bloodstream. A small study performed in 13 PD patients using [11C]DASB PET showed an 
inverse correlations between [11C]DASB and Pittsburgh compound B distribution volume ratios 
in the neocortex and striatum (Kotagal, Bohnen, et al., 2012). These findings have been confirmed 
recently in a bigger population, for the neocortex but not for the striatum (Kotagal et al., 2018). 
In the same study, it has been demonstrated that the use of SSRIs for at least 6 months was 
associated with a lower level of CSF Aβ1-42 and with lower risk of cognitive decline (Kotagal et 
al., 2018). This confirms the hypothesis that that serotonergic terminals are important in the 
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clearance of Aβ and indirectly to the development of cognitive impairment. The relationship 
between serotonergic system and accumulation of misfolded proteins open to a fascinating 
hypothesis on its potential connection with the deposition of Lewy bodies. However, to test this 
hypothesis in vivo, it will be necessary to have, alongside with [11C]DASB, a α-synuclein PET 
tracer which is currently unavailable.    
 
A postsynaptic component of cognitive disturbances can also be speculated in PD. Twelve control 
subjects and 12 PD patients were examined with PET using the 5-HT1B-radioligand 
[11C]AZ10419369. In PD patients, 5-HT1B-receptor availability in the right orbitofrontal cortex 
was lower than in control subjects. Lower 5-HT1B-receptor availability correlated with older age 
in the right temporal cortex in control subjects and for the right midbrain and left parahippocampal 
gyrus in PD patients (Varrone et al., 2014). PD patients showed also lower measures of semantic 
and episodic memory, as well as creative ability, compared with control subjects. Greater creative 
ability correlated with 5-HT1B receptor availability in grey matter, and in PD patients between 
scores of Beck Depression Inventory-II and creative ability (Varrone et al., 2015). 
 
6.6.Neuropsychiatric disturbances 
In addition to depression, several neuropsychiatric disturbances are common in PD, including 
apathy, visual hallucinations and psychosis. Apathy is characterized by a diminished goal-
oriented behavior, and reduction in emotional expression (Starkstein, 2012). About one third of 
PD patients develop apathy in the course of the disease, although it is often confused with 
dementia or depression, of which it can also be an integral part (Pagonabarraga, Kulisevsky, 
Strafella, & Krack, 2015). In PD patients, the main mechanism identified in the development of 
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apathy is dopaminergic (Wen, Chan, Tan, & Tan, 2016), although recently a presynaptic 
serotonergic component has been described (Maillet et al., 2016). In this study, [11C]DASB and 
[11C]PE2I PET were used in 15 apathetic and 15 non-apathetic early drug-naïve PD patients. PD 
patients with apathy showed a 21-58% [11C]DASB binding reduction in the striatum compared to 
PD patients without apathy, with similar [11C]PE2I binding. Lower [11C]DASB binding in the 
caudate and in the orbitofrontal cortex correlated with the severity of apathy (Maillet et al., 2016). 
Interestingly, in this population with early disease, there was a more pronounced reduction in 
serotonergic than in dopamine terminals in those with apathy, thus challenging the concept of 
predominantly dopaminergic involvement in early disease stages (Schrag & Politis, 2016). These 
findings may also change the treatment of apathy in PD, options for which are current limited, 
and medications that act on serotonergic targets may assume a major role in the next future.  
 
About 50% of PD patients experiences visual hallucinations (Williams & Lees, 2005). A PET 
study with [18F]setoperone, a selective 5-HT2A receptor radioligand, showed that PD patients with 
visual hallucination have an increased 5-HT2A binding in ventral visual pathway, dorsolateral 
prefrontal cortex, medial orbitofrontal cortex, and insula (Ballanger et al., 2010). These findings 
suggested that abnormalities in serotonin neurotransmission could be involved in the neural 
mechanisms underlying the development of visual hallucinations that is associated with PD, and 
support the use of selective 5-HT2A receptor antagonists in the treatment of visual hallucinations 
in PD (Ballanger et al., 2010). 
 
Psychosis may occur in more than 40% of PD patients leading to increased nursing home 
placements, and higher rates of morbidity (Marsh et al., 2004). The treatment of psychosis in PD 
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is complicated by the D2 antagonist effect of typical and atypical antipsychotics, which may 
worsen motor and cognitive PD symptoms (Ffytche et al., 2017). There is evidence suggesting 
that the serotonergic system maybe involved in the pathophysiology of psychosis in PD (Ffytche 
et al., 2017; Zahodne & Fernandez, 2008). Pimvanserin is a selective 5-HT2A antagonist/inverse 
agonist that showed to be efficacious on psychotic-like behavioral deficits in a 6-week, 
randomised, double-blind, placebo-controlled phase 3 study (Cummings et al., 2014). These 
findings confirm a key role of serotonergic system in the development of psychosis in PD. 
 
 
 
7. SEROTONERGIC SYSTEM CHANGES IN ASYMPTOMATIC LRRK2 
CARRIERS: COMPENSATION, OR DIFFERENT PATHOLOGY? 
Mutations in LRRK2 are associated with the highest genetic attributable risk factor for familial 
and idiopathic forms PD (Kalia et al., 2015). The clinical features of manifesting LRRK2 
mutation carriers are generally indistinguishable from those of patients with idiopathic PD but the 
non-motor features of LRRK2 PD may be less prominent, include better olfactory performance, 
and less cognitive decline, compared to idiopathic PD (Healy et al., 2008). A recent dopaminergic 
and serotonergic PET imaging study in LRRK2 mutation carriers with and without manifest PD 
have been performed, who they assessed in parallel with a cohort of individuals with idiopathic 
PD and healthy controls (Wile et al., 2017). LRRK2 mutation carriers with manifest PD and 
idiopathic PD patients showed a reduction in dopaminergic [18F]DOPA and [11C]DTBZ binding 
in the striatum, whereas LRRK2 mutation carriers without manifest disease were largely 
unaffected. However, several LRRK2 mutation carriers without manifest PD showed reduction 
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of DAT, assessed with [11C]d-threo-methylphenidate PET scans. Interestingly, LRRK2 mutation 
carriers without manifest PD showed an increase in [11C]DASB binding in the hypothalamus, 
striatum, and brainstem in comparison with all other study populations. LRRK2 mutation carriers 
with manifest PD and individuals with idiopathic PD showed a similar reduced expression of 
striatal [11C]DASB binding (Wile et al., 2017). These findings challenge the classic pathological 
interpretation of disease progression. If the midbrain raphe nucleus is affected in a 
presymptomatic stage according to Braak, and LRRK2 pathological features are similar to those 
seen in idiopathic PD, serotonergic PET would have shown decreases rather than increases. As 
described above, serotonergic PET studies in idiopathic PD have shown a progressive and non-
linear loss of serotonergic terminals (Politis, Wu, Loane, Kiferle, et al., 2010). Only two PET 
studies have reported relative increases in the expression of [11C]DASB in the hypothalamus, 
striatum, and brainstem in idiopathic PD patients with depressive symptoms (Boileau et al., 2008; 
Politis, Wu, Loane, Turkheimer, et al., 2010) and weight changes (Politis, Loane, et al., 2011) 
compared with individuals with idiopathic PD but without depressive symptoms and weight 
changes (but not with healthy controls). This finding suggests that elevated expression of 
serotonin transporters was probably a concurrent occurrence with serotonergic terminal loss in 
the individuals with idiopathic PD (Politis, 2017). Unfortunately, data for depression were 
reported in only five LRRK2 mutation carriers without manifest PD who were assessed with the 
self-reported Beck Depression Inventory, with no data related to weight changes or other non-
motor symptoms, therefore limiting interpretation. Moreover, expression of serotonin transporters 
in LRRK2 mutation carriers without manifest PD was increased, compared with healthy controls, 
which might indicate serotonergic terminals affected by Parkinson’s pathology (Wile et al., 2017). 
In such a scenario, upregulation of serotonin transporters might be secondary to decreases in 
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synaptic serotonin levels and, therefore, indirect PET measures of synaptic serotonin release 
could help elucidate mechanisms in LRRK2 mutation carriers without manifest PD. However, to 
better understand these findings, additional studies are needed in a larger cohort of LRRK2 
mutation carriers without manifest PD, including thorough clinical assessments for depression, 
weight changes, and other non-motor symptoms, and perhaps longitudinal observations to 
elucidate molecular changes over time and their associations with clinical symptoms. 
 
 
8. CONCLUSIONS AND FUTURE DIRECTIONS 
The serotonergic system is emerging as a dynamic player within not only motor and non-motor 
symptoms but also on the development and progression of the disease. The regional cerebral 
biodistribution of serotonergic nerve terminals in the brain can be associated with specific 
biological dysfunctions. Reduced raphe-thalamic serotonergic activity associates with the 
presence of tremors in PD. Abnormal serotonergic sprouting in the striatum is one of the 
determinants of LIDs and GIDs. Limbic serotonergic changes are an important determinant of 
sleep and neuropsychiatric-related disorders. Serotonergic system seems central in the clearance 
of misfolded proteins, in particular Aβ deposition, with dramatic implication for the development 
of cognitive impairments. However, serotonergic functions extend well beyond current 
understanding. Whilst a plethora of symptoms has now been associated with serotonergic 
dysfunction, there are as yet no treatments that specifically target these deficits in PD. Future 
studies should additionally explore the involvement of other 5-HT receptors in the development 
of motor and non-motor symptoms and complications. PET with [11C]Cimbi-36, a 5HT2AR 
agonist, has shown higher sensitivity for changes in synaptic serotonin  levels compared to other 
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5HT PET ligands, and may  eventually allow indirect measures of serotonin release in health 
and parkinsonism (Yang et al., 2017). Emerging evidence of serotonergic changes in 
asymptomatic LRRK2 mutation carriers may be cardinal in the identification of the earliest 
changes involved in the development of PD. In fact, although some risk factors (i.e. rapid eye 
movement sleep behavior disorder, anosmia, and constipation) have been suggested for 
development of idiopathic PD, people with these symptoms, who might be considered as having 
prodromal idiopathic PD, provide limited possibilities to study premotor pathology because not 
all people at risk will eventually develop PD, and observation of such individuals needs very long 
follow-up periods. Studies in genetic populations without manifest PD, such as the asymptomatic 
LRRK2 mutation carriers, provide a good opportunity to understand the mechanisms underlying 
the premotor stages of PD. Advances in PET will allow novel investigations of molecular 
pathology in vivo (tau, synaptic and mitochondria pathology) and these studies will be important 
for understanding premotor stages and progression of PD. Such studies might also be expanded 
to include carriers of the rarer—but more penetrant—autosomal dominant mutation in the gene 
encoding α-synuclein (SNCA), which is directly implicated in Lewy body pathology and in PD 
susceptibility (Politis, 2017). 
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Figure captions 
Figure 1. Serotonergic nerve terminal figure illustrating presynaptic and postsynaptic molecular 
serotonergic imaging targets. Abbreviations: SERT = Serotonin Transporter; 5HT-R = 5-
hydroxytryptamine Receptor.  
Figure 2. Summed [11C]DASB PET images coregistered and fused with 3T MRI images at the 
level of the dorsal basal ganglia for a healthy subject with normal dopaminergic and serotonergic 
innervation (A); a Parkinson’s patient (57 years old, disease duration 52 months, MDS-UPDRS-
III of 28) with stable response to levodopa with loss of serotonergic and dopaminergic innervation 
(B); and a Parkinson’s patient (56 years old, disease duration 58 months, MDS-UPDRS-III of 33)  
who experiences levodopa-induced dyskinesia with a loss of dopaminergic innervation but 
preserved serotonergic innervation (C). 
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Table 1.  Overview of serotonin receptors and PET radioligands  
Overview of serotonin receptors 
Receptor 
Receptor 
Sub-type 
PET Ligand Used in PD Function Agonists Antagonists 
5-HT1 5-HT1A 
[11C]WAY100635, [18F]MPPF, [11C]CUMI-
101 
Doder et al. found in 26 PD 
patients compared to 8 healthy 
controls that midbrain raphe 
[11C]WAY100635 binding was 
reduced by 27% in PD patients 
and there was a significant 
correlation between reductions 
in midbrain raphe 
[11C]WAY100635binding and 
the severity of resting tremor 
(Doder et al., 2003).                 
Compared with controls, 
nondepressed parkinsonian 
patients presented reduced 
[18F]MPPF uptake bilaterally 
in the inferior frontal cortex as 
well as in the right ventral 
striatum and insula. Compared 
with controls, [18F]MPPF 
uptake was decreased in 
depressed parkinsonian 
patients in the left dorsal 
anterior cingulate and 
orbitofrontal cortices, in the 
right hippocampic region, and 
in the temporal cortex 
(Ballanger et al. 2012). 
Addiction, 
Aggression, 
Anxiety, Appetite, 
Autoreceptor, 
Blood Pressure. 
Cardiovascular 
Function, Emesis, 
Heart Rate, 
Impulsivity, 
Memory, Mood, 
Nausea, 
Nociception, 
Erection, Pupil 
Dilation, 
Respiration, 
Sexual Behavior, 
Sleep, Sociability, 
Thermoregulation 
and 
Vasoconstriction 
Selective (for 5-HT1A over 
other 5-HT receptors) 
Vilazodone (Viibryd), F-
15,599 (research compound, 
highly potent and selective 
for 5-HT1A), Flesinoxan 
(potent, EC50 = 24 nM), 
Gepirone (partial agonist, Ki 
= 70 nM), Haloperidol, 
Ipsapirone (partial agonist, 
Ki = 12.1 nM), Quetiapine, 
Trazodone, Yohimbine 
(unselective partial agonist), 
Tandospirone (potent and 
selective partial agonist) 
Nonselective 
5-CT (potent - Ki = 250±50 
pM), 8-OH-DPAT (potent), 
Aripiprazole (atypical 
antipsychotic), Asenapine 
(atypical antipsychotic), 
Buspirone (partial agonist), 
Vortioxetine (high-efficacy 
partial agonist), Ziprasidone 
(Partial agonist, Ki = 3.4 
nM), Methylphenidate 
(weak agonist) 
BMY 7378, 
Cyanopindolol, 
Iodocyanopindolol, 
Lecozotan, 
Methiothepin, 
Methysergide, NAN-
190, Nebivolol, 
Nefazodone, WAY-
100,135, WAY-
100,635, Mefway 
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5-HT1B [11C]AZ10419369, [11C]P943 
Twelve control subjects and 12 
PD patients were examined 
with PET using the 5-HT1B-
radioligand [11C]AZ10419369. 
In PD patients, 5-HT1B-
receptor availability in the 
right orbitofrontal cortex was 
lower than in control subjects. 
Lower 5-HT1B-receptor 
availability correlated with 
older age in the right temporal 
cortex in control subjects and 
for the right midbrain and left 
parahippocampal gyrus in PD 
patients (Varrone et al. 2014). 
PD patients showed also lower 
measures of semantic and 
episodic memory, as well as 
creative ability, compared with 
control subjects. 
Greater creative ability 
correlated with 5-HT1B 
receptor availability in grey 
matter, and in PD patients 
between scores of Beck 
Depression Inventory-II and 
creative ability (Varrone et al. 
2015). 
Addiction, 
Aggression, 
Anxiety, 
Autoreceptor, 
Learning, 
Locomotion, 
Memory, Mood, 
Erection, Sexual 
Behavior, 
Vasoconstriction 
5-CT, CGS-12066A, CP-
93,129, CP-94,253, 
Dihydroergotamine, 
Eltoprazine, Ergotamine, 
Methysergide, RU 24969, 
TFMPP, Triptans 
(antimigraine), Zolmitriptan, 
Eletriptan, Sumatriptan, 
Vortioxetine (partial agonist, 
Ki = 33 nM) 
Alprenolol, AR-
A000002, Asenapine, 
Cyanopindolol, GR-
127,935, 
Iodocyanopindolol, 
Isamoltane, 
Metergoline, 
Methiothepin, 
Oxprenolol, Pindolol, 
Propranolol, SB-
216,641, Yohimbine 
5-HT1D [11C]P943 No studies in PD patients. 
Anxiety, 
Autoreceptor, 
Locomotion, 
Vasoconstriction 
5-CT, CP-135,807, 
Dihydroergotamine, 
Ergotamine, Methysergide, 
Triptans (antimigraine), 
Almotriptan, Eletriptan, 
Frovatriptan, Naratriptan, 
Rizatriptan, Sumatriptan, 
Zolmitriptan, Yohimbine 
BRL-15572, GR-
127,935, Ketanserin, 
Metergoline, 
Methiothepin, 
Rauwolscine, 
Ritanserin, 
Vortioxetine (Ki = 54 
nM), Ziprasidone 
5-HT1E Under development No studies in PD patients. Unknown BRL-54443 Unknown 
5-HT1F Under development No studies in PD patients. Migrane 
BRL-54443, Lasmiditan, 
LY-334,370, Naratriptan, 
Eletriptan 
Unknown 
  59 
5-HT2 
5-HT2A 
[11C]MDL100907, [18F]altanserin, 
[18F]setoperone, [11C]Cimbi-36, [11C]N-
methylspiperone 
Patients having PD with visual 
hallucinations demonstrate 
increased [18F]setoperone 5-
HT2A receptor availability in 
the ventral visual pathway 
(including the bilateral 
inferooccipital gyrus, right 
fusiform gyrus, and 
inferotemporal cortex) as well 
as the bilateral dorsolateral 
prefrontal cortex, medial 
orbitofrontal cortex, and insula 
(Ballanger et al. 2010) 
Addiction 
(potentially 
modulating), 
Anxiety, Appetite, 
Cognition, 
Imagination, 
Learning, 
Memory, Mood, 
Perception, Sexual 
Behavior, Sleep, 
Thermoregulation, 
Vasoconstriction 
25I-NBOMe (Full agonist), 
2C-B, 5-MeO-DMT, BZP, 
Bufotenin, DMT, DOM, 
Ergonovine, Lisuride, LSD, 
Mescaline, Myristicin, PNU-
22394 (Partial agonist), 
Psilocin, Psilocybin, TFMPP 
(partial agonist or 
antagonist) 
Atypical 
antipsychotics 
Clozapine, 
Olanzapine, 
Quetiapine, 
Risperidone, 
Ziprasidone, 
Aripiprazole, 
Asenapine, 
Amitriptyline, 
Clomipramine, 
Cyproheptadine, 
Eplivanserin, 
Etoperidone, 
Haloperidol, 
Hydroxyzine, 
Iloperidone,  
Ketanserin 
(antihypertensive), 
Methysergide, 
Mianserin, 
Mirtazapine, 
Nefazodone, 
Pimavanserin, 
Pizotifen, Ritanserin, 
Trazodone, 
Yohimbine 
5-HT2B Under development No studies in PD patients. 
Anxiety, Appetite, 
Cardiovascular 
Function, Gut 
Motility, Sleep, 
Vasoconstriction 
BW-723C86, Fenfluramine, 
MDMA, Norfenfluramine, 
PNU-22394,  (Partial 
agonist), Ro60-0175, 
Methylphenidate (weak 
agonist) 
Agomelatine, 
Asenapine, BZP, 
Ketanserin, 
Methysergide, 
Ritanserin, RS-
127,445, Tegaserod, 
Yohimbine 
5-HT2C [18F]fluorophenethoxy)pyrimidine No studies in PD patients. 
Addiction. 
(potentially 
modulating), 
Anxiety, Appetite, 
Gut Motility, 
Heteroreceptor for 
A-372,159, AL-38022A, 
Aripiprazole, Ergonovine, 
Lorcaserin, PNU-22394 
(Full agonist), Ro60-0175, 
TFMPP, Trazodone, 
(hypnotic), YM-348 
Agomelatine 
(antidepressant), 
Amitriptyline, 
Asenapine, 
Clomipramine, 
Clozapine, 
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norepinephrine 
and dopamine, 
Locomotion, 
Mood, Erection, 
Sexual Behavior, 
Sleep, 
Thermoregulation, 
Vasoconstriction 
(antipsychotic), 
Cyproheptadine, 
Dimebolin, 
Eltoprazine, 
Etoperidone, 
Fluoxetine, 
Haloperidol, 
Iloperidone, 
Ketanserin,  
(antihypertensive), 
Lisuride, 
Methysergide, 
Mianserin, 
Mirtazapine, 
Nefazodone, 
Olanzapine, 
Paroxetine, 
Quetiapine, 
Risperidone, 
Ritanserin, Tramadol, 
Trazodone, 
Ziprasidone 
5-HT3 / 
[11C]MDL72222, [11C]YM060, [11C]Y-
25130, [11C]KF17643, [11C]S21007, 
[18F]MR18445, [11C]NMQ 
No studies in PD patients. 
Addiction, 
Anxiety, Emesis, 
Gut Motility, 
Learning, 
Memory, Nausea 
2-Methyl-5-HT, BZP, 
Quipazine, RS-56812 
Alosetron, Several 
antiemetics, 
Dolasetron, 
Ondansetron, 
Granisetron, 
Tropisetron, 
Clozapine, 
Memantine, 
Metoclopramide, 
Mianserin, 
Mirtazapine, 
Olanzapine, 
Quetiapine, 
Vortioxetine (Ki = 
3.7 nM) 
5-HT4 / [11C]SB207145, [123I]SB207710 No studies in PD patients. 
Anxiety, Appetite, 
Gut Motility, 
Learning, 
5-MT, BIMU-8, Cinitapride, 
Cisapride (gastroprokinetic), 
Dazopride, Metoclopramide, 
L-Lysine, Piboserod 
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Memory, Mood, 
Respiration 
Mosapride, Prucalopride, 
RS-67333, Renzapride, 
Tegaserod, Zacopride 
5-HT5 
5-HT5A Under development No studies in PD patients. 
Autoreceptor, 
Locomotion, Sleep 
5-CT, Ergotamine, Valerenic 
Acid (partial agonist) 
Asenapine, 
Dimebolin, 
Methiothepin, 
Ritanserin, SB-
699,551, SB-
699,551-A 
5-HT5B Under development No studies in PD patients. Unclear Unclear Unclear 
5-HT6 / 
[11C]GSK215083, [11C]GSK224558, 
[18F]12ST05 
No studies in PD patients. 
Anxiety, 
Cognition, 
Learning, 
Memory, Mood 
EMD-386,088, EMDT 
Amitriptyline, 
Aripiprazole, 
Asenapine, 
Clomipramine, 
Clozapine, 
Dimebolin, EGIS-
12233, Haloperidol, 
Iloperidone, MS-245, 
Olanzapine, Ro04-
6790, SB-258,585, 
SB-271,046, SB-
357,134, SB-399,885 
5-HT7 / [18F]2FP3, [11C]DR4446 No studies in PD patients. 
Anxiety, 
Autoreceptor, 
Memory, Mood,  
Respiration, Sleep, 
Thermoregulation, 
Vasoconstriction 
5-CT, 8-OH-DPAT, 
Aripiprazole (weak partial 
agonist), AS-19, E-55888, 
RA-7 
Amitriptyline, 
Asenapine, 
Clomipramine, 
Clozapine, EGIS-
12233, Haloperidol, 
Iloperidone, 
Imipramine, 
Ketanserin, 
Mirtazapine, 
Olanzapine, 
Ritanserin, 
Risperidone, SB-
269,970, Vortioxetine 
(Ki = 19 nM) 
EC50 = Half maximal effective concentration; ki = Inhibition constant. 
 
